The company announced a transformative $1 billion acquisition into the pharmaceutical sector with significant after-hours stock surge of 47.43%, indicating strong market approval despite regulatory hurdles ahead. The strategic pivot into oncology and autoimmune drug development represents growth potential.
The company announced a significant $1 billion acquisition of ACEA Pharma that expands its operational footprint into the pharmaceutical sector, creating new revenue streams and market opportunities. The stock gained on this news, and the acquisition demonstrates growth ambitions despite trading at a premium valuation.
Phoenix is being acquired and will be transformed into ACEA Pharma, Inc. with a Nasdaq listing, providing access to Scilex's established pharmaceutical operations and commercial products in pain management and other therapeutic areas.
Articles that tag PHOE but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
